SLU-PP-332 Research Guide: A Pan-ERR Agonist

SLU-PP-332 is a synthetic small molecule used as a chemical probe for the estrogen-related receptor family. It is not a peptide. Published work describes it as a pan-agonist of ERR alpha, ERR beta, and ERR gamma and uses it to study transcriptional programs associated with oxidative metabolism, mitochondrial function, exercise response, autophagy, kidney aging, and cardiac stress.

Those findings are preclinical. They come from biochemical assays, cultured cells, human tissue-derived cells exposed outside the body, and mouse models. Exact searches of ClinicalTrials.gov for SLU-PP-332 and SLU-PP-915 returned no study records on July 22, 2026. This guide therefore maps what researchers measured without turning model-specific observations into a human efficacy, safety, pharmacokinetic, or use claim.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic nonsteroidal ligand developed as a research agonist for the estrogen-related receptors. Despite the family name, ERRs are not estrogen receptors and are not activated by estrogen. They are orphan nuclear receptors: transcription factors that bind DNA and regulate gene-expression programs after interacting with ligands, coactivators, and other cellular signals.

The PubChem CID 5338394 record lists formula C₁₈H₁₄N₂O₂, computed molecular weight about 290.3 g/mol, and CAS synonym 303760-60-3. These are registry identity fields. They do not describe a commercial lot, confirm purity, or establish biological performance.

What Does Pan-ERR Agonism Mean?

The ERR family contains three related receptors encoded by ESRRA, ESRRB, and ESRRG, also called NR3B1, NR3B2, and NR3B3. Reviews by Giguere (2008) and Audet-Walsh and Giguere (2015) describe how ERRs integrate with coactivators including PGC-1 alpha and help coordinate oxidative and mitochondrial transcription. Both are narrative reviews of receptor biology, and both report no quantitative endpoint for a synthetic ERR agonist. Calling SLU-PP-332 pan-ERR means assay activity spans all three subtypes; it does not mean that all downstream effects are identical or equally dependent on each receptor.

The subtype distinction matters in the primary papers. Billon et al. (2023) reported that the acute exercise-response program in their tested models depended on ERR alpha, and placed the compound’s highest potency at ERR alpha while reporting no quantitative endpoint for potency. In a mouse pressure-overload cardiac model, Xu et al. (2024) reported an ERR gamma-dependent component, with fatty-acid, lipid and TCA-cycle metabolite profiles measured in mouse hearts after 6-week pressure overload. Those results belong to their respective experiments. They do not create a universal receptor hierarchy.

How Does SLU-PP-332 Work in Research Models?

Nuclear-receptor agonism is better understood as a regulated transcriptional network than as a single on-off switch. In the original report, SLU-PP-332 increased an ERR-linked transcriptional program and type IIa oxidative muscle fibres in mice. The authors also reported greater treadmill endurance in the tested mice. The study supports an acute exercise-response model and a tool for interrogating ERR biology; it does not support the popular label exercise pill for people.

A separate obesity-model study by Billon et al. (2024) reported increased energy expenditure and fatty-acid oxidation together with changes in fat mass and metabolic measures in mice. The models were diet-induced obese and genetically obese ob/ob mice, and the reported direction was decreased fat-mass accumulation with improved insulin sensitivity; the paper states no quantitative result for either. The correct translation is narrow: an ERR agonist altered those endpoints under that mouse-study design. It is not evidence of human weight loss, a treatment effect, or a general metabolic-safety profile.

Other papers widen the pathway map without eliminating its boundaries. Losby et al. (2024) connected ERR agonism with TFEB and autophagy regulation in neonatal rat ventricular myocytes and mouse C2C12 myoblasts, where TFEB behaved as a direct ERR target gene; that report gives no quantitative finding. The 2026 SLU-PP-332/SLU-PP-915 comparison reported induction of Ddit4, a stress-responsive transcriptional signal, for both compounds. These findings indicate testable nodes in a network; they do not prove one complete mechanism across tissues or species.

What Evidence Exists for SLU-PP-332?

The current evidence is easiest to interpret by model rather than by headline. Each layer answers a different question, and none substitutes for a controlled human exposure study.

Wang et al. (2023) treated 21-month-old mice for 8 weeks and reported reversal of the age-related rises in albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines, through cyclic GMP-AMP synthase-STING and STAT3 signalling. Xu and colleagues studied pressure overload in mice and evaluated both SLU-PP-332 and the later analog SLU-PP-915: both compounds improved ejection fraction, ameliorated fibrosis and increased survival in that mouse model without affecting cardiac hypertrophy, and genetic-dependency experiments placed ERR gamma as the mediator; the paper reports no quantitative effect size for ejection fraction or survival. These are disease-context experiments, but disease-model efficacy is not clinical efficacy, and an animal cardiac result cannot establish cardiac safety in people.

The human-tissue language requires special care. Bonanni et al. (2025) obtained muscle biopsies and then treated primary myoblast cultures derived from that tissue. The pilot enrolled 20 women undergoing hip arthroplasty, n = 10 self-reported active and n = 10 inactive; the treated primary cultures were established from the inactive group, and exposure lowered NOX4 and raised SIRT1, PGC-1 alpha, ERR alpha and FNDC5, with differentiation into myotubes followed over 15 days. The study can inform how human-derived cells respond under culture conditions. It is not a human exposure trial, and it provides no human pharmacokinetic, tolerability, or outcome data.

SLU-PP-332 vs SLU-PP-915

SLU-PP-915 is not another name for SLU-PP-332. It is a chemically distinct pan-ERR agonist reported in a later medicinal-chemistry program. Billon et al. (2026) compared the compounds under overlapping mouse exercise criteria and reported oral activity for SLU-PP-915 in mice. SLU-PP-915 matched SLU-PP-332 for running distance and duration by the intraperitoneal route and held comparable efficacy orally once adjusted for systemic exposure, and both compounds induced Ddit4; the paper reports no quantitative outcome for either. That paper makes a scientific comparison possible, but it does not establish a human winner.

Two 2026 analytical studies mapped metabolites in human-liver S9 or microsomal test systems: Moller et al. and Avliyakulov et al. Moller and colleagues identified 9 SLU-PP-332 metabolites, 6 Phase I and 3 Phase II conjugates, alongside 7 Phase-I products for SLU-PP-915. Avliyakulov and colleagues identified 22 SLU-PP-332 metabolites in pooled human liver S9, among them 5 monohydroxylated, 3 dihydroxylated and 4 reduced dihydroxylated species, with 8 of them the most abundant and potentially useful for doping control. Both are identification studies and report no quantitative result for exposure, clearance, or half-life. In-vitro metabolism experiments help identify possible transformation products. They do not establish oral bioavailability, circulating exposure, clearance, or half-life in a person.

Evidence Gaps and Registry Status

The central unresolved questions are translational. The published record does not establish human pharmacokinetics, bioavailability, dose-response, target engagement, short- or long-term safety, interaction risk, or efficacy. It also does not show that a commercial research material is analytically equivalent to the test articles used in each paper. Those gaps cannot be filled by extrapolating from formula, mouse outcomes, cultured human-derived cells, or an in-vitro metabolite map.

A sound research plan therefore starts with a defined question and model: which ERR subtype or transcriptional output, which cell or organism, what exposure confirmation, what positive and negative controls, and what analytical record for the material? The design should preserve the difference between receptor engagement, transcriptional response, organism-level phenotype, and any later translational question.

How to read an SLU-PP-332 claim

Four checks catch most overstatements. First, identify the experimental unit: purified receptor, cultured cell, tissue-derived culture, or mouse. Second, name the endpoint that was actually measured, such as reporter activity, gene expression, oxygen consumption, exercise capacity, tissue histology, or a metabolite signal. Third, identify the dependency evidence. A receptor-knockout or pathway-perturbation result is more informative than an association, but it remains bounded to that system. Fourth, ask whether another group has reproduced the result independently.

These checks explain why phrases such as mimics exercise are incomplete. The 2023 paper reported overlap with selected acute exercise transcriptional responses and mouse phenotypes; it did not reproduce every mechanical, neural, vascular, endocrine, or adaptive feature of physical activity. Likewise, a change in energy expenditure in an obesity-model mouse does not predict a person’s body-composition response. The scientific value is the defined ERR perturbation, not the compressed headline.

Material identity is a separate layer. A literature result applies to the test article the investigators used. A new experiment needs its own chain of custody, chemical-identity documentation, appropriate analytical review, solvent and vehicle controls, and stability assumptions suited to the design. A catalog name or computed formula cannot substitute for that record, and a clean analytical result cannot by itself prove the biological claim being tested.

Continue in the Research Library

Continue with the Apex Laboratory Research Library for evidence-led guides, the specialty research compounds hub for adjacent non-peptide topics, and the Editorial Standards for sourcing, review, and correction policy. The site category spans multiple compound classes; its navigation label does not make SLU-PP-332 a peptide.

Frequently Asked Questions